INO
Price
$1.34
Change
+$0.01 (+0.75%)
Updated
Jul 8 closing price
Capitalization
68.29M
MNKD
Price
$3.62
Change
+$0.08 (+2.26%)
Updated
Jul 8 closing price
Capitalization
1.1B
28 days until earnings call
Interact to see
Advertisement

INO vs MNKD

Header iconINO vs MNKD Comparison
Open Charts INO vs MNKDBanner chart's image
Inovio Pharmaceuticals
Price$1.34
Change+$0.01 (+0.75%)
Volume$2.68M
Capitalization68.29M
MannKind
Price$3.62
Change+$0.08 (+2.26%)
Volume$2.54M
Capitalization1.1B
INO vs MNKD Comparison Chart in %
Loading...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INO vs. MNKD commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a Hold and MNKD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (INO: $1.34 vs. MNKD: $3.62)
Brand notoriety: INO: Notable vs. MNKD: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 181% vs. MNKD: 102%
Market capitalization -- INO: $68.29M vs. MNKD: $1.1B
INO [@Biotechnology] is valued at $68.29M. MNKD’s [@Biotechnology] market capitalization is $1.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 0 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • INO’s FA Score: 0 green, 5 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 5 TA indicator(s) are bullish while MNKD’s TA Score has 3 bullish TA indicator(s).

  • INO’s TA Score: 5 bullish, 5 bearish.
  • MNKD’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, INO is a better buy in the short-term than MNKD.

Price Growth

INO (@Biotechnology) experienced а -34.31% price change this week, while MNKD (@Biotechnology) price change was +1.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

INO is expected to report earnings on May 13, 2025.

MNKD is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.1B) has a higher market cap than INO($68.3M). INO YTD gains are higher at: -24.719 vs. MNKD (-43.701). MNKD has higher annual earnings (EBITDA): 82.6M vs. INO (-93.37M). MNKD has more cash in the bank: 182M vs. INO (68.4M). INO has less debt than MNKD: INO (11.3M) vs MNKD (47.2M). MNKD has higher revenues than INO: MNKD (298M) vs INO (283K).
INOMNKDINO / MNKD
Capitalization68.3M1.1B6%
EBITDA-93.37M82.6M-113%
Gain YTD-24.719-43.70157%
P/E RatioN/A36.20-
Revenue283K298M0%
Total Cash68.4M182M38%
Total Debt11.3M47.2M24%
FUNDAMENTALS RATINGS
INO vs MNKD: Fundamental Ratings
INO
MNKD
OUTLOOK RATING
1..100
551
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
46
Fair valued
PROFIT vs RISK RATING
1..100
10059
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
9490
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (46) in the Biotechnology industry is in the same range as INO (50) in the Medical Specialties industry. This means that MNKD’s stock grew similarly to INO’s over the last 12 months.

MNKD's Profit vs Risk Rating (59) in the Biotechnology industry is somewhat better than the same rating for INO (100) in the Medical Specialties industry. This means that MNKD’s stock grew somewhat faster than INO’s over the last 12 months.

INO's SMR Rating (98) in the Medical Specialties industry is in the same range as MNKD (100) in the Biotechnology industry. This means that INO’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Price Growth Rating (90) in the Biotechnology industry is in the same range as INO (94) in the Medical Specialties industry. This means that MNKD’s stock grew similarly to INO’s over the last 12 months.

MNKD's P/E Growth Rating (99) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that MNKD’s stock grew similarly to INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INOMNKD
RSI
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HEMAX10.420.06
+0.58%
Janus Henderson Emerging Markets A
NWHOX29.310.04
+0.14%
Nationwide Bailard Tech & Sci A
OISVX14.35N/A
N/A
Optimum Small-Mid Cap Value Instl
DQIYX32.99N/A
N/A
BNY Mellon Equity Income Fund Y
MKVGX15.99N/A
N/A
MFS International Large Cap Value R4

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with RPTX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
+0.75%
RPTX - INO
58%
Loosely correlated
+7.75%
AXON - INO
53%
Loosely correlated
-1.49%
ARRY - INO
52%
Loosely correlated
-6.60%
ONCO - INO
50%
Loosely correlated
+11.37%
BCYC - INO
48%
Loosely correlated
+4.60%
More